CMMB CHEMOMAB THERAPEUTICS LTD revenue, earnings and financials
For the quarter ended June 30, 2025, CHEMOMAB THERAPEUTICS LTD reported revenue of n/a, net income of −$2.06M and diluted EPS of n/a; for the fiscal year ended December 2025 revenue was n/a.
CMMB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$112M, net income −$9.00M (margin n/a), EPS $0.02
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$103M, net income −$13.9M (margin n/a), EPS $0.04
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income n/a, net income −$24.2M (margin n/a), EPS $0.10
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income n/a, net income −$27.6M (margin n/a), EPS $0.12
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income n/a, net income −$12.5M (margin n/a), EPS $0.06
CMMB quarterly revenue and earnings
- Quarter ended Jun 30, 2025: revenue n/a, net income −$2.06M, EPS n/a
- Quarter ended Mar 31, 2025: revenue n/a, net income −$3.32M, EPS n/a
- Quarter ended Jun 30, 2024: revenue n/a, net income −$3.63M, EPS $0.01
- Quarter ended Mar 31, 2024: revenue n/a, net income −$3.87M, EPS n/a
- Quarter ended Jun 30, 2023: revenue n/a, net income −$7.97M, EPS $0.04
- Quarter ended Mar 31, 2023: revenue n/a, net income −$8.75M, EPS $0.04
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$8.27M, EPS $0.04
- Quarter ended Sep 30, 2022: revenue n/a, net income −$8.08M, EPS $0.04
- Quarter ended Jun 30, 2022: revenue n/a, net income −$6.19M, EPS $0.03
- Quarter ended Mar 31, 2022: revenue n/a, net income −$5.10M, EPS $0.02
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$5.04M, EPS $0.02
- Quarter ended Sep 30, 2021: revenue n/a, net income −$2.97M, EPS $0.01
- Quarter ended Jun 30, 2021: revenue n/a, net income −$2.77M, EPS $0.01
- Quarter ended Mar 31, 2021: revenue n/a, net income −$1.70M, EPS $0.01
CMMB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$11.1M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$15.4M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$23.6M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$20.4M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$12.4M, share buybacks n/a
CMMB balance sheet
- Dec 31, 2025: cash $7.56M, total assets $13.8M, total liabilities $1.48M, shareholders' equity $12.3M
- Jun 30, 2025: cash $5.45M, total assets $11.1M, total liabilities $1.43M, shareholders' equity $9.70M
- Dec 31, 2024: cash $6.07M, total assets $17.0M, total liabilities $3.43M, shareholders' equity $13.5M
- Jun 30, 2024: cash $5.04M, total assets $14.5M, total liabilities $4.56M, shareholders' equity $9.99M
- Dec 31, 2023: cash $9.29M, total assets $22.2M, total liabilities $5.15M, shareholders' equity $17.0M
- Jun 30, 2023: cash $10.4M, total assets $28.8M, total liabilities $6.86M, shareholders' equity $22.0M
- Mar 31, 2023: cash $20.8M, total assets $35.0M, total liabilities $7.06M, shareholders' equity $28.0M
- Dec 31, 2022: cash $13.5M, total assets $43.1M, total liabilities $6.84M, shareholders' equity $36.2M
Is CMMB profitable?
No. CHEMOMAB THERAPEUTICS LTD lost $9.00M in its latest fiscal year.